PARIS and BOSTON, April 22, 2024 – In a significant development in the biopharmaceutical industry, Ipsen and Skyhawk Therapeutics have entered into an exclusive global agreement to advance the discovery and development of novel small molecules that target RNA. These...
The review sheds light on the role of post-transcriptional RNA modifications in normal hematopoietic development and acute myeloid leukemia, and highlights novel therapeutic targets and treatment approaches. Credit: Chinese Medical Journal The hematopoietic system is...
CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage immunology company, today announced it will be providing updates on its RNA immunotherapies at multiple presentations at the American Association...
Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable...
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the...